The U.S. Food and Drug Administration (FDA) gave the greenlight to Sanofi’s Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor. Sarclisa is an intravenous (IV) drug, a CD38-directed cytolytic antibody.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,